MA39722A - Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 - Google Patents

Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11

Info

Publication number
MA39722A
MA39722A MA039722A MA39722A MA39722A MA 39722 A MA39722 A MA 39722A MA 039722 A MA039722 A MA 039722A MA 39722 A MA39722 A MA 39722A MA 39722 A MA39722 A MA 39722A
Authority
MA
Morocco
Prior art keywords
gdf11
activin
anemia
inhibition
prevention
Prior art date
Application number
MA039722A
Other languages
English (en)
French (fr)
Inventor
John Knopf
Ravindra Kumar
Naga Venkata Sai Rajasekhar Suragani
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of MA39722A publication Critical patent/MA39722A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA039722A 2014-03-21 2015-03-20 Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11 MA39722A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461969073P 2014-03-21 2014-03-21
US201462021923P 2014-07-08 2014-07-08

Publications (1)

Publication Number Publication Date
MA39722A true MA39722A (fr) 2021-06-02

Family

ID=54145413

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039722A MA39722A (fr) 2014-03-21 2015-03-20 Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11

Country Status (9)

Country Link
US (2) US20160046690A1 (2)
EP (1) EP3119418B1 (2)
JP (2) JP2017509647A (2)
KR (2) KR102520970B1 (2)
CN (1) CN106659769A (2)
AU (3) AU2015231022B2 (2)
CA (1) CA2942954A1 (2)
MA (1) MA39722A (2)
WO (1) WO2015143403A1 (2)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
JP2018501307A (ja) 2014-12-03 2018-01-18 セルジーン コーポレイション アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用
MA41119A (fr) 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
CA2983440C (en) 2015-04-22 2024-03-12 Alivegen Usa Inc. Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
WO2017079591A2 (en) 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
EP3380121B1 (en) 2015-11-23 2023-12-20 Acceleron Pharma Inc. Actrii antagonist for use in treating eye disorders
MA45811A (fr) * 2016-07-27 2019-06-05 Acceleron Pharma Inc Méthodes et compositions de traitement de maladie.
CA3036104A1 (en) * 2016-09-15 2018-03-22 Acceleron Pharma Inc. Twisted gastrulation polypeptides and uses thereof
CN110036025B (zh) * 2016-10-05 2024-03-22 阿塞勒隆制药公司 变体ActRIIB蛋白及其用途
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
NZ754161A (en) 2016-11-10 2025-11-28 Keros Therapeutics Inc Activin receptor type iia variants and methods of use thereof
PL3638243T3 (pl) 2017-06-14 2025-02-10 Celgene Corporation Sposoby leczenia mielofibrozy związanej z nowotworem mieloproliferacyjnym i niedokrwistości
CN107828719B (zh) * 2017-09-14 2020-05-19 暨南大学 Gdf11在脂肪间充质干细胞成骨分化中的应用
CA3082146A1 (en) 2017-11-09 2019-05-16 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
WO2019213016A1 (en) * 2018-04-30 2019-11-07 The Children's Hospital Of Philadelphia Methods of improving anemias by combining agents
KR20250133994A (ko) 2018-05-09 2025-09-09 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
WO2021149925A1 (ko) * 2020-01-20 2021-07-29 루다큐어 주식회사 Trpv1 활성 매개 질환 치료용 약학적 조성물
WO2021189010A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
WO2021189019A1 (en) 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Activin receptor type ii chimeras and methods of use thereof
WO2023212296A1 (en) * 2022-04-29 2023-11-02 University Of Massachusetts Selective rna-modulating agents
WO2025040002A1 (zh) * 2023-08-21 2025-02-27 苏州炫景生物科技有限公司 靶向inhbe基因的双链寡核苷酸、缀合物、组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877075A4 (en) * 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
US8128933B2 (en) * 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CN104524548A (zh) * 2006-12-18 2015-04-22 阿塞勒隆制药公司 活化素-actrii拮抗剂及在提高红细胞水平中的用途
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TW201803586A (zh) * 2008-08-14 2018-02-01 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
KR20120049214A (ko) * 2009-06-08 2012-05-16 악셀레론 파마 인코포레이티드 발열성 지방세포를 증가시키는 방법
AU2010282361B2 (en) 2009-08-13 2015-03-19 Acceleron Pharma Inc. Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels
WO2012027065A2 (en) * 2010-08-27 2012-03-01 Celgene Corporation Combination therapy for treatment of disease
KR20140084211A (ko) * 2011-10-17 2014-07-04 악셀레론 파마 인코포레이티드 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물
EP2844668A1 (en) * 2012-05-03 2015-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment and diagnotic of anemia of inflammation
HK1214504A1 (zh) * 2012-10-24 2016-07-29 细胞基因公司 用於治療貧血的方法

Also Published As

Publication number Publication date
WO2015143403A1 (en) 2015-09-24
EP3119418A4 (en) 2018-01-03
KR20160127148A (ko) 2016-11-02
AU2021200301A1 (en) 2021-03-18
EP3119418A1 (en) 2017-01-25
US20210155672A1 (en) 2021-05-27
EP3119418B1 (en) 2022-02-23
AU2023219885A1 (en) 2023-09-14
CN106659769A (zh) 2017-05-10
JP7154250B2 (ja) 2022-10-17
KR20230004942A (ko) 2023-01-06
JP2020111621A (ja) 2020-07-27
CA2942954A1 (en) 2015-09-24
AU2015231022B2 (en) 2021-02-04
JP2017509647A (ja) 2017-04-06
KR102520970B1 (ko) 2023-04-12
AU2015231022A1 (en) 2016-09-29
US20160046690A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
MA39722A (fr) Composition pour son utilisation dans une methode de traitement ou de prevention de l'anemie par l'inhibition de l'activine b et du gdf11
EP3374502A4 (en) METHOD FOR THE TREATMENT OF CORNEAL DYSTROPHIES
EP3302379A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PTERYGIUM
EP3347469A4 (en) METHOD AND COMPOSITIONS FOR TREATING GLAUCOMA
EP3368559A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3233878A4 (en) PHOSPHORAMIDATE FOR THE TREATMENT OF HEPATITIS C VIRUS
EP3390642A4 (en) COMPOSITIONS AND METHODS OF TREATING RETINITIS PIGMENTOSA 18 AND RETINITIS PIGMENTOSA 13
EP3380200A4 (en) COMPOSITIONS FOR TREATING THE HAIR
MA43283A (fr) Procédés et compositions pour le traitement du cancer
EP3341391A4 (en) COMPOSITIONS AND METHODS OF PAIN TREATMENT
EP3362065A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF MALIGNITIES
EP3503890A4 (en) USE OF PRIDOPIDIN FOR THE TREATMENT OF DYSTONIA
EP3380063A4 (en) COMPOSITIONS FOR TREATING THE HAIR
EP3334432A4 (en) CERDULATINIB FOR THE TREATMENT OF MYELOMA
EP3429609A4 (en) COMPOSITIONS AND METHOD FOR TREATING DEFECTS OF COLLAGEN TYPE VII
EP3347025A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
EP3353204A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MA43230A (fr) Méthodes et compositions pour le traitement d'une épidermolyse bulleuse
EP3386967A4 (en) COMBINATIONS FOR TREATING KIDNEY STONES
EP3848022C0 (en) THERAPEUTIC AGENT FOR USE IN THE TREATMENT OF INFECTION
EP3522865A4 (en) METHOD AND COMPOSITIONS FOR TREATING STRIAE DISTENSAE
EP3365014A4 (en) METHOD AND COMPOSITIONS FOR TREATING SYSTEMIC MASTO CYTOSIS
EP3386593A4 (en) IMMUNOMODULATING COMPOSITION FOR TREATMENT
EP3329929A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DRY EYES
EP3331545A4 (en) FOR EXTRACELLULAR HEMICAN DOMAIN SPECIFIC MEANS FOR THE TREATMENT OF SEPSIS